Press

Psychedelics Venture Capital Firm Iter Investments to Exhibit/Host Events at Wonderland: Miami by Microdose from Nov. 8-9, 2021

Oct 29 • 4 min read

Fort Lauderdale, Florida – Iter Investments, a venture capital firm that deploys capital primarily in businesses operating in and around the burgeoning psychedelic industry, will exhibit at Wonderland: Miami by Microdose from Nov. 8-9, 2021 at the Adrienne Arsht Center for the Performing Arts in Miami. The event is known as, “The Largest Psychedelic Medicine Business…

Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program

Oct 29 • 3 min read

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced today the success of phase one of its new chemical entity (NCE) development program to strengthen Awakn’s pipeline for the treatment of a broad range of both substance and behavioral addictions. Novel MDMA-like…

Cybin Announces FDA Investigational New Drug Authorization of Cybin’s Sponsored Feasibility Study using Kernel Flow Technology

Oct 29 • 3 min read

Cybin Inc. (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, today announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the Company’s sponsored feasibility study using Kernel’s Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. “The word psychedelic means…

MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program

Oct 29 • 4 min read

Mind Medicine Inc. (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its pipeline with the launch of a program to develop R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses that include Autism Spectrum Disorder (ASD). This program represents a significant expansion and diversification of…

Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder

Oct 22 • 3 min read

Quick Take: Lead candidate SPL026 granted MHRA Innovation Passport Designation Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with the U.K. Medicines and Healthcare products Regulatory Agency, Small Pharma has been granted an Innovation Passport Designation for SPL026, the lead product candidate…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441